Cell-free DNA in Acute Stroke

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the role of cell-free DNA (cfDNA) in patients who have had an acute stroke, specifically those caused by a blockage in a large blood vessel. Researchers want to understand how cfDNA, which is a part of our DNA found in the bloodstream, might affect inflammation and blood clotting during a stroke. They will analyze cfDNA from both the blood and the blood clots removed during a procedure called mechanical thrombectomy, which is done to restore blood flow in stroke patients. The goal is to learn more about how cfDNA relates to different types of strokes and treatment outcomes.

To be eligible for this trial, participants must be adults aged 18 or older who have experienced an acute ischemic stroke due to a large vessel blockage and require a thrombectomy. However, individuals currently receiving treatments that affect the immune system, those with certain immune diseases, or those with infections at the time of their stroke will not be included. If you join the trial, you can expect to provide blood samples for analysis and help researchers gain valuable insights that could improve stroke treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
• • 18 years of age
• Exclusion Criteria:
• • Patients currently undergoing immunological therapies.
• • Patients with immunological diseases
• • Patients with systemic infections at the time of admission